LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inexpensive Diagnostic Device May Revolutionize Medical Care

By LabMedica International staff writers
Posted on 28 Feb 2017
Image: The lab-on-a-chip comprises a clear silicone microfluidic chamber for housing cells and a reusable electronic strip — a flexible sheet of polyester with commercially available conductive nanoparticle ink (Photo courtesy of Zahra Koochak, Stanford University).
Image: The lab-on-a-chip comprises a clear silicone microfluidic chamber for housing cells and a reusable electronic strip — a flexible sheet of polyester with commercially available conductive nanoparticle ink (Photo courtesy of Zahra Koochak, Stanford University).
A radically designed “lab on a chip” diagnostic device is expected to dramatically reduce the cost of isolating and characterizing rare cells and molecules, a process that is of critical importance in diagnosis of common lethal diseases such as malaria, tuberculosis, HIV, and cancer.

Point-of-care diagnostics in the developing world and resource-limited areas require numerous special design considerations to provide effective early detection of disease. Of particular need for these contexts are diagnostic technologies featuring low costs, ease of use, and broad applicability. Investigators at Stanford University recently described a nanoparticle-inkjet-printable microfluidics-based platform that fulfilled these criteria and that is expected to significantly reduce the footprint, complexity, and cost of clinical diagnostics. This reusable 0.01 USD device is miniaturized to handle small sample volumes and can perform numerous analyses.

The device is a combination of microfluidics, electronics, and inkjet printing technology. It is in essence a two-part system: a clear silicone microfluidic chamber for housing cells resting on top of a reusable electronic strip. A regular inkjet printer was used to print the electronic strip onto a flexible sheet of polyester using commercially available conductive nanoparticle ink.

The device, which separates cells based on their size and intrinsic electrical properties, can perform label-free and rapid single-cell capture, efficient cellular manipulation, rare-cell isolation and selective analytical separation of biological species, sorting, concentration, positioning, enumeration, and characterization. The miniaturized format allows for small sample and reagent volumes. By keeping the electronics separate from microfluidic chips, the former can be reused and device lifetime is extended.

The process of manufacturing the device is significantly less expensive, time-consuming, and complex than traditional lab-on-a-chip platforms, requiring only an inkjet printer rather than skilled personnel and clean-room facilities. Production requires only about 20 minutes (versus up to weeks) and one US cent - an unprecedented cost in in clinical diagnostics.

“The genome project has changed the way an awful lot of medicine is done, and we want to continue that with all sorts of other technology that are just really inexpensive and accessible,” said senior author Dr. Ronald W. Davis, professor of biochemistry and genetics at Stanford University. “The motivation was really how to export technology and how to decrease the cost of things.”

A study describing the technology was published in the February 6, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more